Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Akari Therapeutics ADR (AKTX)

Akari Therapeutics ADR (AKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,639
  • Shares Outstanding, K 45,784
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,790 K
  • EBIT $ -19 M
  • EBITDA $ -19 M
  • 60-Month Beta 0.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.19
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings $0.00 on 11/13/25
  • Next Earnings Date 04/15/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1300 +5.77%
on 03/23/26
0.2811 -51.09%
on 03/11/26
-0.1175 (-46.08%)
since 02/24/26
3-Month
0.1300 +5.77%
on 03/23/26
0.3150 -56.35%
on 01/05/26
-0.1297 (-48.54%)
since 12/24/25
52-Week
0.1300 +5.77%
on 03/23/26
1.5800 -91.30%
on 04/22/25
-1.3125 (-90.52%)
since 03/24/25

Most Recent Stories

More News
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating...

AKTX : 0.1375 (-5.17%)
Akari Therapeutics Announces ADS Ratio Change

TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating...

AKTX : 0.1375 (-5.17%)
Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala

Highlights strategic progress achieved under Abizer Gaslightwala’s leadership, including advancement of AKTX-101 and expansion of Akari’s ADC pipeline  Access the Akari CEO Corner here ...

AKTX : 0.1375 (-5.17%)
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology...

AKTX : 0.1375 (-5.17%)
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology...

AKTX : 0.1375 (-5.17%)
Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference

TAMPA, Fla. and LONDON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology...

AKTX : 0.1375 (-5.17%)
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline

CEO Abizer Gaslightwala discusses the Company’s recent announcement around its ADC pipeline expansion and IP strategy Company also discusses its lead ADC program, AKTX-101, and its planned IND...

AKTX : 0.1375 (-5.17%)
JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026

Register for the two-day virtual event here

AKTX : 0.1375 (-5.17%)
AIM : 0.9705 (+1.52%)
DCOY : 7.27 (-2.68%)
BULL : 5.13 (-3.39%)
GRI : 2.43 (-6.18%)
MBRX : 2.25 (+7.14%)
Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

–  Live video webcast on Tuesday, February 10 th at 1:00 PM EST TAMPA, Fla. and LONDON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX ), an oncology biotechnology...

AKTX : 0.1375 (-5.17%)
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1 spliceosome payload and a novel antibody construct...

AKTX : 0.1375 (-5.17%)

Business Summary

Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5,...

See More

Key Turning Points

3rd Resistance Point 0.1614
2nd Resistance Point 0.1542
1st Resistance Point 0.1458
Last Price 0.1375
1st Support Level 0.1302
2nd Support Level 0.1230
3rd Support Level 0.1146

See More

52-Week High 1.5800
Fibonacci 61.8% 1.0261
Fibonacci 50% 0.8550
Fibonacci 38.2% 0.6839
Last Price 0.1375
52-Week Low 0.1300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.